BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Metabolon Awarded Biomarker Study Collaboration With Massachusetts General Hospital And The University Of Pittsburgh School of Medicine Funded By The ALS Association


10/19/2005 5:09:59 PM

RESEARCH TRIANGLE PARK, N.C., Feb. 12 /PRNewswire/ -- Metabolon, Inc. today announced its collaboration with Massachusetts General Hospital and the University of Pittsburgh School of Medicine on a new biomarker study funded by The ALS Association (ALSA).

Researchers will work together on the study, Identification of Diagnostic Biomarkers and Therapeutic Targets for ALS, to find a more rapid and accurate diagnostic test for ALS using biomarkers found in cerebrospinal fluid and blood. They will analyze blood and cerebrospinal fluid from a control group and from ALS patients using two different technologies.

Metabolon will test samples obtained from patients using its metabolomics platform that will search for signatures of ALS by measuring the spectrum of biochemical changes and mapping these changes in metabolic pathways. In pilot studies, Metabolon has established metabolic profiles from the blood of ALS patients for comparison to profiles from control groups. Metabolon will be able to extend its findings by expanding the study to a larger sample set and analyzing the profiles in cerebrospinal fluid.

"There is an urgent need to find a faster and more reliable diagnostic process that will enable earlier treatment and improve chances that therapy will alter the course of ALS," said Dr. Lucie Bruijn, science director and vice president of The ALS Association.

"We are delighted to be working with ALSA on this project, and we are committed to make a difference in the lives of ALS patients," said Rima Kaddurah-Daouk, Ph.D., co-founder of Metabolon and a principal researcher in the new study. "Using our innovative metabolomics approach, we will be evaluating global biochemical defects in ALS in ways not possible before. We will ultimately be able to draw a map that can highlight diagnostic markers for ALS and novel targets for drug design."

The study was initiated by ALSA as part of its Lou Gehrig Challenge, a privately funded research program aimed at finding effective treatments for and, ultimately, a cure for ALS. The project is being funded for one year with the possibility for renewal after presentation of the initial data to the Lou Gehrig Challenge Scientific Advisory Committee.

About Metabolon:

Metabolon is a leader in the application of metabolomics, a powerful and new scientific approach for the discovery and development of drugs and the early diagnosis of disease states. Seasoned and successful entrepreneurs, as well as scientific pioneers, make up Metabolon's executive management team and boards.

Metabolon's patent-pending technology is poised to dramatically impact drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten the time for drugs to get to market and identify diagnostic markers for earlier disease detection. For additional information, visit http://www.metabolon.com/ .

About ALSA:

The ALS Association is the only national not-for-profit voluntary health organization dedicated solely to the fight against amyotrophic lateral sclerosis through research, patient support, information dissemination and public awareness. For additional information, contact The ALS Association at (818) 880-9007 or visit http://www.alsa.org/ .

Metabolon, Inc.

CONTACT: Reid Tripp, Vice President of Metabolon, +1-919-597-6592, orrtripp@metabolon.com; or Scott Place of Maverick Marketing, for Metabolon,+1-919-484-4184, or Cell, +1-919-271-5788, or Fax, +1-800-856-3274, orsplace@maverickmarketing.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES